Sugi Predict

Sugi Predict / Compounds / SCHEMBL7922271

SCHEMBL7922271

SCHEMBL7922271

Cc1cc2nc(C)sc2cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ ALDH1A1 P00352 3/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ RAB9A P51151 2/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ TP53 P04637 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ PKM P14618 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ GAA P10253 1/20 0.55
▸ ALOX15 P16050 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ CHRNB2 P17787 1/20 0.40
▸ CHRNA4 P43681 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7920616 0.83 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL25604729 0.80 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL23705799 0.80 KMT2A (0.42) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL17053159 0.78 NPC1 (0.41) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL14046219 0.77 SMN1; SMN2 (0.34) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL4384430 0.77 SMN1; SMN2 (0.85) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL12635465 0.75 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL12810048 0.73 PIK3CD (0.56) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL24845433 0.72 MAPK14 (0.41) MAPT
SCHEMBL17053157 0.72 DYRK1A (0.32) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4190784-A1 NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2023-06-07 — — EP disclosed
EP-3426653-B1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA (CH) 2021-12-15 — — EP disclosed
WO-2021155320-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
WO-2021155264-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
US-20200299305-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA 2020-09-24 — — US disclosed
US-20190071450-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA (CH) 2019-03-07 — — US disclosed
WO-2017153601-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA (CH) 2017-09-14 — — WO disclosed
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 — — US disclosed
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 — — US disclosed
EP-2649062-B1 BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) TAKEDA PHARMACEUTICAL (JP) 2015-04-08 — — EP disclosed
US-20120142714-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 — — US disclosed
US-20120142714-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 — — US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 — — US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 — — US disclosed
WO-2011136385-A1 BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-03 — — WO disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 — — EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 — — WO disclosed
WO-2004014384-A2 CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071450-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY SNCA, PARK7, NLN SMN1; SMN2 23/4885ALDH1A1 1936/4885NPC1 1677/4885
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB SMN1; SMN2 787/4885ALDH1A1 762/4885NPC1 978/4885
US-20200299305-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY SNCA, PARK7, NLN SMN1; SMN2 23/4885ALDH1A1 1936/4885NPC1 1677/4885
US-20110263562-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB SMN1; SMN2 1489/4885ALDH1A1 583/4885NPC1 1126/4885
US-20120142714-A1 BICYCLIC COMPOUND ACACA, ACACB, FABP4 SMN1; SMN2 4073/4885ALDH1A1 172/4885NPC1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.